Posttreatment with the immunosuppressant cyclosporin A in transient focal ischemia

Brain Research

Volumn 839, Issue 2, 1999, Pages 283-291

  Yoshimoto, Tetsuyuki ^a   Siesjö, Bo K ^a  

^a QUEEN S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MANNITOL; TACROLIMUS; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG PENETRATION; DRUG SAFETY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIA; MALE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NEUROPROTECTION; NONHUMAN; OSMOSIS; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD GLUCOSE; BLOOD-BRAIN BARRIER; BODY TEMPERATURE; BRAIN INJURIES; CARBON DIOXIDE; CAROTID ARTERIES; CYCLOSPORINE; DIURETICS, OSMOTIC; HYDROGEN-ION CONCENTRATION; IMMUNOSUPPRESSIVE AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRA-ARTERIAL; ISCHEMIC ATTACK, TRANSIENT; MALE; MANNITOL; OSMOSIS; OXYGEN; RATS; RATS, WISTAR; SODIUM CHLORIDE; TACROLIMUS; WOUNDS, STAB;

EID: 0033612939     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01733-3     Document Type: Article

References (46)

1. Atkinson K., Biggs J., Darveniza P., Boland J., Concannon A., Dodds A. Cyclosporin-associated central nervous system toxicity after allogenic bone marrow transplantation. Transplantation. 38:1984;34-37.
2. Barth R.F., Yang W., Rotaru J.H., Moeschberger M.L., Joel D.D., Nawrocky M.M., Goodman J.H., Soloway A.H. Baron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res. 57:1997;1129-1136.
3. Bederson J.B., Pitts L.H., Germano S.M., Nishimura M.C., Davis R.L., Bartkowski H.M. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 17:1986;1304-1308.
4. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 17:1986;472-476.
5. Bernardi P., Petronilli V. The permeability transition pore as a mitochondrial calcium release channel: a critical appraise. J. Bioenerg. Biomembr. 28:1996;131-137.
6. Bullard D.E., Binger S.H., Binger D.D. Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res. 45:1985;5240-5245.
7. Butcher S.P., Henshall D.C., Teramura Y., Iwasaki K., Sharkey J. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J. Neurosci. 15:1997;6939-6946.
8. 2 supply/consumption heterogeneity. J. Cereb. Blood Flow Metab. 16:1996;323-333.
9. Dawson T.M., Steiner J.P., Dawson V.L., Dineman J.L., Uhl G.R., Snyder S.H. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxity. Proc. Natl. Acad. Sci. U.S.A. 90:1993;9808-9812.
10. Duchen M., McGuinness O., Brown L., Crompton M. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc. Res. 27:1993;1790-1794.
11. Eckman W.W., Patlak C.S., Fenstermacher J.D. A critical evaluation of the principles governing the advantages of the intraarterial infusions. J. Pharmacokinet. Biopharm. 2:1974;257-285.
12. Friberg H., Ferrand-Drake M., Bengtsson F., Halestrap A.P., Wieloch T. Cyclosporin A, but not FK506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J. Neurosci. 15:1998;5151-5159.
13. Gunter T., Pfeiffer D. Mechanisms by which mitochondria transport calcium. Am. J. Physiol. 258:1990;755-786.
14. Ho S., Clipstone L., Northrop J., Graef I., Fiorentino D., Nourse J., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 80:1996;40-45.
15. Karibe H., Zarow G.J., Weinstein P.R. Use of mild intraischemic hypothermia versus mannitol to reduce infarct size after temporary middle cerebral artery occlusion in rats. J. Neurosurg. 83:1995;93-98.
16. Koizumi J., Yoshida Y., Nakazawa T., Ooneda G., Solomon R.A. Experimental studies of ischemic brain edema: 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn. J. Stroke. 8:1986;1-8.
17. Kroll R.A., Neuwelt E.A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 42:1998;1083-1100.
18. Kuroda S., Katsura K., Hillered L., Bates T.E., Siesjö B.K. Delayed treatment with a-phenyl-N-tert-butyl Nitrone (PBN) attenuates secondary mitochondrial dysfunction after transient focal cerebral ischemia in the rat. Neurobiol. Dis. 3:1996;149-157.
19. Kuroda S., Siesjö B.K. Post ischemic administration of FK506 reduces infarct volume following transient focal brain ischemia. Neurosci. Res. Commun. 19:1996;83-90.
20. S. Kuroda, R. Tsuchidate, M.-L. Smith, K.R. Maples, B.K. Siesjö, Neuroprotective effects of a novel nitrone, NXY-059, following transient focal cerebral ischemia in the rat, J. Cereb. Blood Flow Metab. (1999) (in press).
21. Li P.A., Uchino H., Elmér E., Siesjö B.K. Amelioration by cyclosporin A of brain damage following 5 or 10 min of ischemia in rats subjected to preischemic hyperglycemia. Brain Res. 753:1997;133-140.
22. Liu J. FK506 and cyclosporin: molecular probes for studying intracellular signal transduction. Trends Pharmacol. Sci. 14:1993;182-188.
23. Liu J., Farmker J.D., Lane W.S., Freidman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 66:1991;807-815.
24. Longa E., Weinstein P., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniotomy in rats. Stroke. 20:1989;84-91.
25. Luvisotto T.L., Auer R.N., Sutherland G.R. The effect of mannitol on experimental cerebral ischemia, revisited. Neurosurgery. 38:1996;131-139.
26. McDonald J.W., Goldberg M.P., Gwag B.J., Chi S.-I., Choi D.W. Cyclosporin induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures. Ann. Neurol. 40(5):1996;750-758.
27. Moia L.J.M.P., Matsui H., de Barros G.A.M., Tomizawa K., Miyamoto K., Kuwata Y., Tokuda M., Itano T., Hatase O. Immunosuppressants and calcineurin inhibitors, cyclosporin A and FK506, reversibly inhibit epileptogenesis in amygdaloid kindled rat. Brain Res. 648:1994;337-341.
28. Nakai A., S Kuroda S., Kristian T., Siesjö B.K. The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat. Neurobiol. Dis. 4:1997;288-300.
29. Nieminen A.L., Petrie T.G., Lemasters J.J., Selman W.R. Cyclosporin A delays mitochondrial depolarization induced by N-methyl-D-asparate in cortical neurons: evidence of the mitochondrial permeability transition. Neuroscience. 75:1996;993-997.
30. Paczynski R.P., He Y.Y., Diringer M.N., Hsu C.Y. Multiple-dose mannitol reduces brain water content in a rat model of cortical infarction. Stroke. 28:1997;1437-1444.
31. Rapoport S.I. Opening of the blood-brain barrier by acute hypertension. Exp. Neurol. 52:1976;469-479.
32. Sakata A., Tamai I., Kawazu K., Deguchi Y., Ohnishi T., Saheki A., Tsuji A. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem. Pharmacol. 48:1994;1989-1992.
33. Sharkey J., Butcher S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature. 371:1994;336-339.
34. Shiga Y., Onodera H., Matsuo Y., Kogure K. Cyclosporin A protects against ischemia-reperfusion injury in the brain. Brain Res. 595:1992;145-148.
35. Shirai A., Naito M., Tatsuta T., Dong J., Hanaoka K., Mikami K., Oh-hara T., Tsuruo T. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim. Biophys. Acta. 1222:1994;400-404.
36. Shirane R., Weinstein P.R. Effect of mannitol on local cerebral blood flow after temporary complete cerebral ischemia in rats. J. Neurosurg. 76:1992;486-492.
37. Steiner J.P., Connolly M.A., Valentine H.L., Hamilton G.S., Dawson T.M., Hester L., Snyder S.H. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat. Med. 3:1997;421-428.
38. Tamai I., Safa A.R. Competitive interaction of cyclosporin with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 265:1990;16509-16513.
39. P. Tompkins, F.A. Stevens, M.K. Gumerlock, Enhanced delivery of cyclosporin-A to brain with hyperosmolar blood-brain barrier disruption, 27th Annual Meeting, Society for Neuroscience, Vol. 23, Society of Neuroscience, New Orleans, 1997, p. 1165.
40. Uchino H., Elmér E., Lindvall O., Siesjö B.K. Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat. Acta Physiol. Scand. 155:1995;469-471.
41. H. Uchino, E. Elmér, K. Uchino, P.A. Li, Q.P. He, M.L. Smith, B.K. Siesjö, 1998. Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat, Brain Res., pp. 14987-14996.
42. Watanabe T., Kokubu N., Charnick S.B., Naito M., Tsuruo T., Cohen D. Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein. Br. J. Pharmacol. 122:1997;241-248.
43. Yang W., Barth R.F., Moeschberger M.L., Goodman J.H. Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Neurosurgery. 38:1996;985-992.
44. Zhao Q., Pahlmark K., Smith M.-L., Siesjö B.K. Delayed treatment with the spin trap α-phenyl-N-tert-butyl nitrone (PBN) reduces infarct size following transient middle cerebral artery occlusion in rats. Acta Physiol. Scand. 153:1994;349-350.
45. Zoratti M., Szabó I. The mitochondrial permeability transition. Biochim. Biophys. Acta. 1241:1995;139-176.
46. Zunkeler B., Carson R.E., Olson J., Blasberg R.G., DeVroom H., Lutz R.J., Saris S.C., Wright D.C., Kammerer W., Patronas N.J., Dedrick R.L., Herscovitch P., Oldfield E.H. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J. Neurosurg. 85:1996;1056-1065.